ReviewMolecular medicine (Cambridge, Mass.)
Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.
Review in Molecular medicine (Cambridge, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Pooled it
- Pooled it
- Prognostic value of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.Medical oncology (Northwood, London, England) · 2015Pooled it
- Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study.Radiation oncology (London, England) · 2020Trial
- Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.Investigational new drugs · 2014Trial
- Discovery and structural characterization of newcastle disease virus mimetic peptides identified through phage display.Virus research · 2026Article
- An indocyanine green-based liquid biopsy test for circulating tumor cells for pediatric liver cancer.Hepatology communications · 2024Article
- Liquid Biopsies, Novel Approaches and Future Directions.Cancers · 2023Review
- Isolation of Circulating Tumor Cells from Seminal Fluid of Patients with Prostate Cancer Using Inertial Microfluidics.Cancers · 2022Article
- The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy.Turkish journal of urology · 2020Article
- The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.Ecancermedicalscience · 2020Article
- The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.Ecancermedicalscience · 2020Article
- [Circulating tumor cells in pancreatic cancer : Results of morphological and molecular analyses and comparisons with the primary tumor].Der Pathologe · 2018Review
- Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management.Biological research · 2018Review
- Liquid Biopsy in Thyroid Cancer: New Insight.International journal of hematology-oncology and stem cell research · 2018Review
- Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment OutcomeAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Circulating tumor cells in prostate cancer: Precision diagnosis and therapy.Oncology letters · 2017Article
- Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations.Scientific reports · 2017Article
- Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146.Cell death discovery · 2017Review
- KRAS mutations in pancreatic circulating tumor cells: a pilot study.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disseminated malignancy is the major cause of prostate cancer-related mortality. Circulating tumor cells (CTCs) are essential for the establishment of metastasis. Various contemporary and molecular methods using prostate-specific biomarkers have been applied to detect extraprostatic disease that is undetectable by conventional imaging techniques, assessing the risk for disease recurrence after therapy of curative intent. However, the clinical relevance of CTC detection is still controversial. We review current literature regarding molecular methods used for the detection of CTCs in the peripheral blood and bone marrow biopsies of patients with prostate cancer, and we discuss the methodological pitfalls that influence the clinical significance of molecular staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.